Study summary

Isatuximab produced blood responses in about 3 in 4 people with relapsed AL amyloidosis

SWOG S1702 trial · 43 people, phase 2 · Published November 2025, Blood

What was tested

Isatuximab, another CD38 antibody, for relapsed or refractory AL amyloidosis.

What they found

• Hematologic response rate was 77.1%, with 57% reaching very good partial response or better.
• Kidney responses in 50% and heart responses in 57% of evaluable people.
• Responses came fast (median 1.1 months).

What it means

Another option after first treatment, from a US cooperative group trial.